Press release: dupixent recommended for eu approval by the chmp to treat patients with copd

Dupixent recommended for eu approval by the chmp to treat patients with copd recommendation for adults with uncontrolled copd with raised blood eosinophils based on data from two landmark phase 3 trials demonstrating dupixent significantly reduced exacerbations and improved lung function if approved, dupixent would be the first-ever targeted therapy for copd in the eu and the first new treatment approach for this disease in more than a decade paris and tarrytown, n.y. may 31, 2024.
REGN Ratings Summary
REGN Quant Ranking